Xeris Biopharma Exceeds Full-Year 2025 Revenue Guidance with Strong Preliminary Results

summarizeSummary

Xeris Biopharma reported preliminary full-year 2025 revenue of $292 million, exceeding its guidance and reflecting 44% year-over-year growth, alongside positive Adjusted EBITDA and strengthened IP.

check_boxKey Events

• Exceeds Full-Year Revenue Guidance

  Reported preliminary total revenue of $292 million for full-year 2025, surpassing the guidance range of $285-$290 million.

• Strong Year-Over-Year Growth

  Full-year 2025 revenue reflects a 44% increase compared to the prior year, driven by strong product performance.

• Key Product Performance

  Recorlev® net revenue reached $139 million for the full year, with approximately 700 patients on therapy. Gvoke® revenue grew over 13%, and Keveyis® saw a growing patient base.

• Positive Adjusted EBITDA

  The company achieved positive Adjusted EBITDA in every quarter of 2025.

auto_awesomeAnalysis

Xeris Biopharma Holdings, Inc. announced preliminary financial results for the fourth quarter and full year 2025, reporting total revenue of $292 million, which surpassed its previous guidance range of $285-$290 million. This performance represents a significant 44% year-over-year growth, driven by strong contributions from its key products, Recorlev®, Gvoke®, and Keveyis®. The company also achieved positive Adjusted EBITDA in every quarter and strengthened its intellectual property portfolio, indicating robust operational execution and a positive outlook for sustained growth.